Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN versus LINCOMYCIN HCL.
Clindamycin vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
150-450 mg orally every 6 hours; 600 mg to 1.2 g intravenously every 6-8 hours; maximum 4.8 g/day IV.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
2.4 hours (range 1.5-5.1 hours) in adults with normal renal function; prolonged in severe hepatic impairment.
Clinical Note
moderateClindamycin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Clotrimazole
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Approximately 10% of active drug and 90% as inactive metabolites via renal (feces 3.6% as active, bile significant for enterohepatic circulation).
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic
"The metabolism of Clotrimazole can be decreased when combined with Clindamycin."